CSL Ltd. - ADR

CSLLY

Get informed when a big investor buys or sells

Market Cap$120.43B

Close$

Compare to Similar Companies

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
CSL Ltd. - ADR	-23.6	2.31%	3%	2	0.7

Earnings Call Q4 2023

August 15, 2023 - AI Summary

CSL delivered strong full-year results, with revenue up 31% at constant currency and NPATA of $2.6 billion, up 20%.

The CSL Behring business saw strong growth in its Ig franchise, with sales up 21%. Plasma collections reached record levels, and the company dosed its first patients with HEMGENIX, a gene therapy for hemophilia B.

CSL Seqirus achieved strong sales growth, driven by FLUCELVAX, which was up 30%. The company also signed a licensing agreement with Arcturus Therapeutics for next-generation mRNA vaccine technology.

Exclusive for Stockcircle Pro members

$23.93

Current Fair Value

23.6% downside

Overvalued by 23.6% based on the discounted cash flow analysis.

Share Statistics

Market cap	$120.43 Billion
Enterprise Value	$129.81 Billion
Dividend Yield	$0.72 (2.31%)
Earnings per Share	$-1.34
Beta	0.08
Outstanding Shares	1,915,647,916

Return

Return on Equity	3.04%
Return on Assets	1.34%
Return on Invested Capital	28.99%

Valuation & Multiples

P/E Ratio	-23.64
PEG	6.06
Price to Sales	1.96
Price to Book Ratio	3.91
Enterprise Value to Revenue	4.16
Enterprise Value to EBIT	15.82
Enterprise Value to Net Income	288
Total Debt to Enterprise	0.08
Debt to Equity	0.74

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date

August 17, 2026

EPS Estimate

Average shareholder expectation

Revenue Estimate

Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio	0.00000%
Total Calls	-
Total Puts	-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %	0.00%▲ 0.00%
Total Invested	$600,885▼ 57.74%
Investors Holding	6▼ 1.00%

ESG Score